Heska To $165? Plus BTIG Cuts PT On This Stock By 67%

  • BTIG cut the price target on Gain Therapeutics, Inc. GANX from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at $3.21 on Friday.
  • Piper Sandler cut the price target for Heska Corporation HSKA from $170 to $165. Piper Sandler analyst David Westenberg maintained an Overweight rating on the stock. Heska shares rose 0.5% to close at $72.48 on Friday.
  • Evercore ISI Group cut the price target on Neurocrine Biosciences, Inc. NBIX from $140 to $130. Neurocrine Biosciences shares fell 3% to $117.79 in pre-market trading.
  • BMO Capital slashed the price target for CytomX Therapeutics, Inc CTMX from $3 to $2.6. CytomX Therapeutics shares rose 2.4% to close at $1.29 on Friday.
  • Piper Sandler slashed the price target for Elanco Animal Health Incorporated ELAN from $21 to $15. Elanco Animal Health shares gained 10.2% to close at $13.51 on Friday.
  • Keybanc boosted the price target on Meritage Homes Corporation MTH from $87 to $96. Meritage Homes shares gained 3% to $86.26 in pre-market trading.
  • HC Wainwright & Co. cut the price target on Sol-Gel Technologies Ltd. SLGL from $22 to $19. Sol-Gel Technologies shares fell 1.8% to close at $4.80 on Friday.

Check out this: Why MorphoSys Shares Are Trading Lower By Around 32%; Here Are 30 Stocks Moving Premarket

Don’t forget to check out our premarket coverage here .

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: NewsPenny StocksPrice TargetSmall CapPre-Market OutlookMarketsAnalyst RatingsBiotechnologyHealth CarePT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!